Celyad Oncology reports third quarter 2023 financial results and recent business highlights
“Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.
- “Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.
- Celyad Oncology has relocated from September 25, 2023 into a new research facility which fits better its current needs after the strategic shift.
- The Company remains headquartered at the Axis Parc, Mont-Saint-Guibert, Belgium but with its new business location at Dumont 9.
- Net cash burn during the third quarter of 2023 amounted to €2.7 million, in line with expectations.